About MSB
Mesoblast Ltd (MSB), a Health Care constituent on the ASX, is active in developing allogeneic (off-the-shelf) cellular medicines for the treatment of inflammatory conditions. The therapies from the business's proprietary mesenchymal lineage cell therapy technology platform respond to inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in reduction of the damaging inflammatory process.
All News for MSB
No news articles found for MSB yet.